NASDAQ: OXBR
OXBRIDGE RE HOLDINGS LtdCIK 0001584831 · SIC 6331 · Fire, Marine & Casualty Insurance
Every 8-K is open in full. Other 10-Ks and 10-Qs show a 3-bullet preview. A free account reads 3 more full reports a month. Generating a report requires a verified account.
Sign up freeWant to see a complete report first? Today's free report (SAR 10-Q) is open in full — no account needed.
Summary not yet generated.
Summary not yet generated.
Partner
Trade OXBR commission-free
Open an account, get a free stock.
Investing involves risk. Free stock terms apply.
Summary not yet generated.
Oxbridge Re Holdings launches at-the-market offering of up to $1.68 million at $1.03 per share
4 material changes detected. Sign up free to read the summary.
Summary not yet generated.
Summary not yet generated.
Summary not yet generated.
Summary not yet generated.
Summary not yet generated.
Summary not yet generated.
Summary not yet generated.
Summary not yet generated.
Summary not yet generated.
Summary not yet generated.
Latest financial statements
From 10-Q filed Aug 13, 2026 (period ending Jun 30, 2026). As printed on the EDGAR/iXBRL face — not generated by the model.
Consolidated Statements of Operations (Unaudited)
(expressed in thousands of U.S. Dollars, except per share amounts)
| Description | Three months ended June, 30 2026 | Three months ended June, 30 2025 | Six months ended June 30, 2026 | Six months ended June 30, 2025 |
|---|---|---|---|---|
| Revenue | ||||
| Assumed premiums | 314 | 2,222 | 314 | 2,222 |
| Change in unearned premiums reserve | 54 | (1,640) | 610 | (1,046) |
| Net premiums earned | 368 | 582 | 924 | 1,176 |
| SurancePlus management fee income | 501 | 1 | 501 | 1 |
| Net investment and other income | 71 | 93 | 139 | 173 |
| Realized gain on other investments | - | - | - | 35 |
| Unrealized loss on other investments | - | - | - | (20) |
| Change in fair value of equity securities | - | (12) | - | (9) |
| Total revenue | 940 | 664 | 1,564 | 1,356 |
| Expenses | ||||
| Losses and loss adjustment expenses | - | 2,293 | - | 2,293 |
| Policy acquisition costs and underwriting expenses | 44 | 64 | 105 | 129 |
| General and administrative expenses | 603 | 1,257 | 1,126 | 1,762 |
| Total expenses | 647 | 3,614 | 1,231 | 4,184 |
| Income (loss) before income / loss attributable to tokenholders and non-controlling interests | 293 | (2,950) | 333 | (2,828) |
| (Income) loss attributable to tokenholders | (1) | 946 | (3) | 699 |
| Income (loss) before income / loss attributable to non-controlling interests | 292 | (2,004) | 330 | (2,129) |
| (Income) loss attributable to non-controlling interests | (116) | 131 | (132) | 117 |
| Net income (loss) attributable to ordinary shareholders | 176 | (1,873) | 198 | (2,012) |
| Income (loss) per share attributable to ordinary shareholders | ||||
| Basic and Diluted | 0.02 | (0.25) | 0.02 | (0.28) |
| Weighted-average shares outstanding | ||||
| Basic and Diluted | 8,101,374 | 7,442,922 | 7,961,597 | 7,174,014 |
Consolidated Balance Sheets
(expressed in thousands of U.S. Dollars, except per share and share amounts)
| Description | At June 30, 2026 (Unaudited) | At December 31, 2025 |
|---|---|---|
| Assets | ||
| Cash and cash equivalents | 4,111 | 268 |
| Restricted cash and cash equivalents (Cat Re token program) | 3,691 | 6,708 |
| Restricted cash and cash equivalents (HCI 2026 token program) | 12,020 | - |
| Premiums receivable | 307 | 766 |
| Deferred policy acquisition costs | 35 | 102 |
| Operating lease right-of-use assets | 62 | 43 |
| Prepayment and other assets | 132 | 150 |
| Property and equipment, net | 14 | 16 |
| Total assets | 20,372 | 8,053 |
| Liabilities and Shareholders’ Equity | ||
| Liabilities: | ||
| Reserve for losses and loss adjustment expenses | 91 | 91 |
| Notes payable to noteholders | 118 | 118 |
| Premium payable | 31 | - |
| Unearned premiums reserve | 316 | 926 |
| Losses payable | 73 | 73 |
| Operating lease liabilities | 62 | 43 |
| Accounts payable and other liabilities | 329 | 309 |
| Total liabilities | 1,020 | 1,560 |
| Mezzanine Equity | ||
| Due to Cat Re / T20 / T42 tokenholders | 558 | 518 |
| 100,000 HCI 2026 Series A tokens at redemption value of $36 per token | 3,600 | - |
| 100,000 HCI 2026 Series B tokens at redemption value of $49 per token | 4,900 | - |
| 100,000 HCI 2026 Series C tokens at redemption value of $35.20 per token | 3,520 | - |
| Total Mezzanine equity | 12,578 | 518 |
| Shareholders’ equity: | ||
| Ordinary share capital, (par value $0.001, 500,000,000 shares authorized; 8,101,374 and 7,664,122 shares issued and outstanding) | 6 | 6 |
| Additional paid-in capital | 38,516 | 38,047 |
| Accumulated Deficit | (31,936) | (32,137) |
| Total Oxbridge shareholders’ equity | 6,586 | 5,916 |
| Non-controlling interests | 188 | 59 |
| Total shareholders’ equity | 6,774 | 5,975 |
| Total liabilities, mezzanine and shareholders’ equity | 20,372 | 8,053 |
Consolidated Statements of Cash Flows (Unaudited)
(expressed in thousands of U.S. Dollars)
| Description | Six months ended June 30, 2026 | Six months ended June 30, 2025 |
|---|---|---|
| Operating activities | ||
| Net income (loss) attributable to ordinary shareholders | 198 | (2,012) |
| Adjustments to reconcile net income (loss) to net cash provided by operating activities: | ||
| Share-based compensation | 127 | 178 |
| Realized gain on other investments | - | (35) |
| SurancePlus management fee income | (501) | (1) |
| Depreciation and amortization | 2 | - |
| Change in fair value of other investments | - | 20 |
| Change in fair value of equity securities | - | 9 |
| Income (loss) attributable to non-controlling interests | 132 | (117) |
| Change in operating assets and liabilities: | ||
| Operating right-of-use asset | (70) | 52 |
| Operating lease liabilities | 70 | (52) |
| Premiums receivable | 459 | (918) |
| Deferred policy acquisition costs | 67 | (115) |
| Prepayment and other assets | 18 | (23) |
| Reserve for loss and loss adjustment expenses | - | 175 |
| Premium payable | 31 | - |
| Unearned premiums reserve | (610) | 1,046 |
| Accounts payable and other liabilities | 20 | (106) |
| Net cash used in operating activities | (57) | (1,899) |
| Investing activities | ||
| Proceeds from sale of other investments | - | 63 |
| Net cash provided by investing activities | - | 63 |
| Financing activities | ||
| Proceeds from issuance (redemption) of Tokenholders | 40 | (526) |
| Proceeds from issuance of ordinary shares | 342 | 3,122 |
| Proceeds from issuance of HCI 2026 Series A, B & C Tokens | 6,323 | - |
| Proceeds from HCI Additional Collateral Deposit | 6,198 | - |
| Net cash provided by financing activities | 12,903 | 2,596 |
| Cash and cash equivalents, and restricted cash and cash equivalents: | ||
| Net change during the period | 12,846 | 760 |
| Balance at beginning of period | 6,976 | 5,893 |
| Balance at end of period | 19,822 | 6,653 |
| Non-cash investing and financing activities | ||
| Right-of-use lease asset obtained in exchange for operating lease liabilities | 89 | - |
| Reclassification of contributed non-controlling interest | 3 | 104 |
| Reclassification of other liabilities EpsilonCat Re / DeltaCat Re | - | 1,732 |
Amounts as printed on the EDGAR/iXBRL face — (expressed in thousands of U.S. Dollars, except per share amounts); (expressed in thousands of U.S. Dollars, except per share and share amounts); (expressed in thousands of U.S. Dollars). Labels, columns, and figures are the filing face, not a GAAP stencil. Interactive statements & notes on EDGAR ↗